UroGen Pharma Ltd. — Director's Dealing 2022

Mar 29, 2022

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2022-03-25

Reporting Person: Kim Dong (Chief Financial Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	31920	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option (right to buy)	$11.92	2031-11-30	Ordinary Shares (10000)		Direct

Footnotes

F1: One third of the shares underlying the stock option will vest on each of December 1, 2022, December 1, 2023 and December 1, 2024.